Price (delayed)
$1.5
Market cap
$79.9M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.02
Enterprise value
$119.9M
Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada
There are no recent dividends present for MIST.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.